Business Context and Reporting Period
Mustang Bio, Inc. filed a Current Report on Form 8-K dated September 30, 2016, regarding a private placement transaction. The company is incorporated in Delaware and operates from New York, New York.
Key Financial Metrics and Transaction Details
The filing details a Unit Purchase Agreement executed on September 30, 2016. Key financial terms include:
- Gross Proceeds: $12,446,414 from the initial closing.
- Transaction Size: Minimum $10.0 million, maximum $30.0 million (expandable to $70.0 million at the Company's discretion).
- Units Sold: 191.48 Units.
- Securities Issued: 1,914,833 shares of Common Stock and Warrants to purchase 478,708 shares of Common Stock.
- Unit Composition: Each Unit consists of 10,000 shares of Common Stock and Warrants exercisable for 2,500 shares.
- Warrant Terms: Exercise price of $8.50 per share; exercisable immediately for five years.
- Placement Agent Fees: National Securities Corporation (NSC) received a cash fee of $1,264,641 (10% of gross sales) and Placement Agent Warrants to purchase 191,483 shares.
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity positions.
Material Changes
This filing represents a material change in the company's capital structure through the issuance of unregistered equity securities. The transaction was conducted pursuant to exemptions under Section 4(a)(2) and Rule 506 of Regulation D of the Securities Act of 1933.
Outlook, Risks, and Contingencies
Management Commentary: The Company retains the sole discretion to increase the maximum transaction size from $30.0 million to $70.0 million.
Risks and Restrictions: Shares issued in connection with the Transaction may not be offered or sold in the United States absent registration or an applicable exemption. The full terms of the Transaction Documents will be filed in the Quarterly Report on Form 10-Q for the quarter ended September 30, 2016.
Investor Verification Checklist
- Verify the total aggregate proceeds once the transaction is fully completed, as the initial closing of $12.4 million is below the maximum potential $30.0 million (or $70.0 million).
- Confirm the dilution impact of the 1,914,833 shares issued and the 478,708 shares underlying the investor warrants, plus the 191,483 shares underlying the Placement Agent Warrants.
- Review the upcoming Form 10-Q for the full text of the Transaction Documents and any additional terms not summarized in this 8-K.
- Assess the company's cash position post-transaction to determine runway, as no prior liquidity data is provided in this filing.